CD274 and non-small cell lung carcinoma: Although biomarkers such as PD-L1 can serve as predictive indicators interrogated with immune-checkpoint inhibitors and provide hints for treatment decisions [15], identifying high-risk advanced driver gene-negative NSCLC patients to improve clinical outcomes has remained a challenge until now.